Figure 3
Figure 3. Non–bone marrow–derived SR-BI deficiency leads to platelet hyperreactivity and increased platelet cholesterol content. (A) WT platelets in PRP either from WT or SR-BI−/− recipients were stimulated with ADP, PAR4-AP, or convulxin (CVX), and platelet integrin αIIbβ3 activation and P-selectin expression were determined. (B-C) Platelet aggregation in PRP isolated from chimeric WT or SR-BI−/− mice with WT bone marrow was induced by 120μM PAR4-AP and was optically monitored. (B) Quantification of the aggregation data. Data are expressed as maximal amplitude of aggregation within 5 minutes after adding the agonist. (C) Representative aggregation curves are shown. (D-E) Platelets in PRP from chimeric WT or SR-BI−/− mice with WT bone marrow (BM) in panel D as well as from WT and SR-BI−/− mice in panel E were stained with 50 μg/mL filipin to label unesterified cholesterol and analyzed by flow cytometry. All above data are presented as mean ± SEM of at least 3 independent experiments. (F) WT platelets were isolated by gel-filtration from pooled blood of WT chimeras and loaded with cholesterol in vitro by incubation with 75μM cholesterol-chelated MβCD. Incubation with alpha-cyclodextrin (αCD) was used as control. After cholesterol loading, platelets were stimulated with ADP, thrombin, or CVX, and platelet integrin αIIbβ3 activation was determined by FACS analysis. Data are presented as mean ± SEM of measurements after 3 separate cholesterol loading, which were repeated twice. *P < .05, **P < .01, ***P < .001.

Non–bone marrow–derived SR-BI deficiency leads to platelet hyperreactivity and increased platelet cholesterol content. (A) WT platelets in PRP either from WT or SR-BI−/− recipients were stimulated with ADP, PAR4-AP, or convulxin (CVX), and platelet integrin αIIbβ3 activation and P-selectin expression were determined. (B-C) Platelet aggregation in PRP isolated from chimeric WT or SR-BI−/− mice with WT bone marrow was induced by 120μM PAR4-AP and was optically monitored. (B) Quantification of the aggregation data. Data are expressed as maximal amplitude of aggregation within 5 minutes after adding the agonist. (C) Representative aggregation curves are shown. (D-E) Platelets in PRP from chimeric WT or SR-BI−/− mice with WT bone marrow (BM) in panel D as well as from WT and SR-BI−/− mice in panel E were stained with 50 μg/mL filipin to label unesterified cholesterol and analyzed by flow cytometry. All above data are presented as mean ± SEM of at least 3 independent experiments. (F) WT platelets were isolated by gel-filtration from pooled blood of WT chimeras and loaded with cholesterol in vitro by incubation with 75μM cholesterol-chelated MβCD. Incubation with alpha-cyclodextrin (αCD) was used as control. After cholesterol loading, platelets were stimulated with ADP, thrombin, or CVX, and platelet integrin αIIbβ3 activation was determined by FACS analysis. Data are presented as mean ± SEM of measurements after 3 separate cholesterol loading, which were repeated twice. *P < .05, **P < .01, ***P < .001.

Close Modal

or Create an Account

Close Modal
Close Modal